A conbercept dosing regimen of three initial monthly intravitreal injections followed by quarterly treatments appears to be effective in the treatment of neovascular age-related macular degeneration (AMD), yielding visual and anatomic benefits at 3 and 12 months, according to data from the PHOENIX trial.
One in 10 Malay, Indian and Chinese Singaporeans aged ≥40 years undergoes cataract surgery in at least one eye over 6 years, according to data from the Singapore Epidemiology of Eye Diseases (SEED) Study. Diabetes and myopia are modifiable risk factors for cataract prevalence.
The MGDRx EyeBag, a device designed to treat meibomian gland dysfunction, effectively relieves dry eye symptoms, according to a recent study. However, there seems to be little effect on MG function and tear stability.
New drug applications approved by US FDA as of 1 - 15 October 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Treatment with ranibizumab has resulted in robust visual acuity and anatomic improvement in eyes with concurrent diabetic macular oedema (DME) and baseline macular nonperfusion (MNP) despite having worse vision or increased central subfield thickness (CST), according to a posthoc analysis of RIDE and RISE, two phase III randomized controlled trials.
Early intravitreal implantation of the corticosteroid dexamethasone at an interval of ≥4 months provided rapid and significant improvement in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) in patients with macular oedema following branch retinal vein occlusion (BRVO), according to the COBALT* study.
Progressive thinning of the retinal nerve fibre layer (RNFL) in the superior quadrant is apparent in patients with diabetic peripheral neuropathy (DPN), a new prospective longitudinal study has found. This thinning is more pronounced in older individuals.